Evogene Ltd. — Investor Presentation 2022

Sep 15, 2022

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2022

Commission File Number: 001-36187

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street, Park Rehovot, Rehovot P.O.B 4173, Ness Ziona, 7414002, Israel (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

Attached hereto and incorporated by reference herein is the following exhibit:

99.1Evogene Investor Presentation.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD. (Registrant)

Date: September 15, 2022

By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer

DECODING BIOLOGY

INVESTOR PRESENTATION

Ofer Haviv, President & CEO September 2022

Forward Looking Statement

This presentation contains "forvard-looking to future events, and Evoene Ltd (the "Company"), may fron time to the statements. reqarding our outlook or expectations for operating results and/or other matters regarding or affecting us that are considered "forward-boking statements" as defined in the U.S. Private Securites Library and other securites laws, as amended. Statements that are not statements of historical fact may be deements. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "stimated", "intend" and "potential" or vords of sinilar meaning. We are using forward-looking statenents in this presentation when we discuss our value drining, product development and launches, estimated market sizes and miestones, pipeline, as well as our capabilities and technology.

Such statements are based on current expections and assumptions, describe opinions about future events, involve certain risks and uncertaintes which are difficult to predict and are of future performance. Readers are cautioned that certain inportant factors nay affect the Company's actual results and could cause such rem any forward-looking statements that may be made in this presentation. Therefore, actual future results, performance or acheve in the future may differ materially from what is expessed or implied by such forward-loking statements due to a variety of factors, many of whiching, without limitation, those described in greater detail in Evogene's Annua Report on Form 20-F and in other information Evogene files to the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities we digation or commitment to update any information contained in this presentation or to publicy release the results of any revisions to any be made to reflect future events or changes in expectations, estinates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or offer to sell, or any solicitation of any invitation or offer to purchas of Evogene or the Company, nor shall the information or any part of the fact of its distribution for the basis of, or be relied on inch, any action, contract, commitment or relaing thereto or to the securities of Evolene or the Company.

The trademarks included herein are the property of the owners only. Such use should not be construed as an endorsement of our products or services.

evogene

Agenda

* About Evogene

Business model Product-oriented subsidiaries

Summary

Annex I - Financial Fundamentals

OUR VISION

Revolutionizing life-science based product discovery & development, utilizing cutting edge computational biology technologies.

evøgene

DECODING BIOLOGY

Life-science product development

Low probability of success with high cost and long time-to-market

Pharmaceutical Industry

Cost of developing a single pharmaceutical drug

In the 1970's

\$180 million

In recent years >\$2 billion Ag-chemicals Industry

Years to develop a new crop protection product

1995	2000		2005-8 2010-15
3	0	10	11+

Surces: COR (Center for Dry Administration, Tuts Senter the Study of Dug Deelopment: https://www.sieneednec.com/sience/arch/s/ad/s/1/2016/6000291/a/%Db/id ntops //www.froles.org/sternery/2017/01/2014 - cost-ol-el-same-oper-the-age-chan-el-cod/sm-233862499 Pillips Housely Strage Resert 2022, Sangelor, How Nort of Cost to Reserch and Device a New Drug 7 A Systematic Review and Assessment, August 2010/2/2027-0273-021-0100 Public of Press https://www.cbo.gov/system/files/2021-04/57025-Rx-RnD.pdf

Life-science product development The ultimate case of finding "the needle in the haystack"

The challenge: Finding the winning candidates out of a vast number of possible prospects that address a complex myriad of criteria, to reach successful products

evolgene

The opportunity

Utilizing an advanced computational biology platform

To identify the most promising candidates addressing multiple development challenges towards successful life-science products

• · Increase probability of success
• · Reduce time and cost

Biology meets disruptive technologies

Incorporates deep scientific understandings together with big data and advanced AI technologies, to successfully discover & guide the development of novel life-science based products.

evolgene

Tailor-made Tech Engines for product discovery & development

The CPB platform enhances product discovery and development through dedicated Technology Engines for products based on three core components:

• · Microbes
• · Small molecules
• · Genetic elements

evogene

Example of Tech Engine User Interface @yicro

evøgene

Tailor-made Tech Engines for product discovery & development

+ Discovery

Computational selection of the most promising candidates to initiate the product development process.

+ Development

Computational driven solution addressing optimization development challenges for the selected candidates, without impairing their ability to address other product attributes, supporting the way to successful commercialization.

evogene

Building an 'Ecosystem around our tech engines

evøgene

Annex I - Financial Fundamentals

Evogene Tech Engine - Potential Addressable Markets

evøgene

Product-oriented subsidiaries powered by Evogene's technology

Establish independent entities focusing on a defined commercial field with a license to use Evogene's unique solutions for product development

Subsidiaries:

casterra Ag-solutions for castor

Licensed to use Evogene's tech engines:

evøgene

Collaborations powered by Evogene's technology for the development of innovative products

Joint development with leading companies for defined products utilizing Evogene's unique solution. Typically, partner leads later-stage development and product commercialization.

Powered by Evogene's technological engines:

Evogene Tech Engine - Current Utilization

evogene

Annex I - Financial Fundamentals

* Evogene holdings

evogene

Mission:

Discovery and development of novel therapies for microbiome-related human disorders using computational biology

Product Pipeline:

S

Immuno-oncology program

• · Combination therapy for cancer with checkpoint inhibitors
• · Pre-clinical stage
• · Addressable market size expected by 2026* \$243B

GI related disorders

• · Inflammatory Bowel Disorder (IBD) pre-clinical stage
• · Irritable Bowel Syndrome (IBS) discovery stage
• · Addressable market size expected by 2026: Inflammatory Bowel Disorder \$22.4B, Irritable Bowel Syndrome** \$3.3B

Antimicrobial resistance (AMR)

• · Antimicrobial resistance (AMR)
• · Clostridium Difficile Infection (CDI) discovery stage
• · Methicillin-resistant Staphylococcus aureus (MRSA) discovery stage
• · Addressable market size expected by 2026: CDI*** \$1.7B, MRSA**** \$3.9B

Expected main near-term value drivers:

2022

• · IBD initiate scale-up for GMP production of drug candidate for IBD
• · Immuno-oncology first data point readout from proof of concept, first in human study

2023

• · IBD Clinical batch production of drug candidate for IBD as preparation for Phase 1 in USA
• · Immuno-oncology Pre-IND Meeting with FDA

*https://www.dlobenews.vire.com/news-release/2019/07/17/188418/0/er/Cancer-Immundtherapy-Market-To-Reach-JSD-242-96-Blilion-Br-2026-Reports-Md-Data.html ** to strene and contrass release dealers (and make on success and mail the supers) and medianelers (and 17 light, including consistent consistent police in consistent in and that in a productive a pay in finance (one described) in a leader nation (1) 2006 min 1920 mm (1925 concess not 2005 million (1920) in 1920 million (1920) in 1920 bronnel mar grand-view-research-inc

** (top://ww.gond-innesarch.com/pres-rease-to-teater-halset ton, successfully.com/strip-restory.com/species/freshibit/suble_informations/freship.com/thately.php/including/des this : // www.grold.com/th/side/search.com/todate-in-text-lease-ide-early.com/s/2009/02009/20020.www.gbdata.com/gball.com/gbb/ doddian-office-infode-inform-stream-sport-1-200 ** * may may microsoft dollar in the estable carrisons are environment of engles on on 9-0 Million your in e 3-0 Million your le of Million your the consisted on the control

Powered by

Example Results:

Immuno-Oncology program - BMC128 potentiate the effect of anti-PD-1 therapy (immunotherapy) in-vivo

Improved antitumor activity in mice following the administration of BMC128, compared to treatment with immunotherapy alone

evogene

Biomica Announces Successful Enrollment of First Patient in its Phase I Study of Microbiome-Based Immuno-Oncology Drug

Proof of Concept (POC) in-human trial to take place at Rambam Health Care Campus in Israel throughout 2022

Biomica Announces First Patient Dosed in its Phase I Study of its Microbiome-Based Immuno-Oncology Drug

Mission:

Improve food quality, sustainability and aqriculture productivity through microbiome technology and products

Product Pipeline:

Bio-stimulants (yield enhancement)

• · Bio-stimulants 1- focus on wheat and additional cereals. Seed treatment/soil application. Commercial stage, first sales planned in 2022. Addressable market size * : for spring wheat ±25M acres.
• Bio-stimulants 2 focus on corn and additional crops. Seed treatment. Pre-development stage. Addressable market size*: for corn - 120M acres.

Bio-pesticides (crop protection)

· Fruit rots - focus on fruit and vegetables. Foliar application. Target market*: >\$1B of chemicals usage. Development stage 2.

• Downey Mildew Focus on fruit and vegetables. Foliar
• application. Development stage 1. Target market *: >\$350M of chemicals usage.
• Seedling disease for corn and soy. Seed treatment. predevelopment stage. Target market * : >\$500M.
• · Bio-insecticides for corn and soy. Seed treatment/foliar. Pre-development stage. Target market *: >\$1.5B existing traits & chemicals market.

Expected main near-term value drivers:

2022

• · Bio-stimulants build infrastructure for scale-up in 'Thrivus™' sales for spring wheat in 2023
• · Fruit rot bio-fungicides file for requlatory approval for leading product candidate LAV.311 targeting fruit rot

2023

• · Bio-stimulants 'Thrivus™' product sales expansion in US and Canada for spring wheat
• · Bio-fungicides final preparation for filing for regulatory approval for leading product candidate LAV321 or LAV322 for downy mildew

*Dean, R, .et al. [202]. The top 10 fungal pathology, Molecular Plant Pathology 13:414-430 (https://addemi.coup.com/toplarticle/2/3/11/5057759

Example Results:

• Thrivus™ inoculant
• LAV 311 & LAV 312 leading bio-fungicide candidates for fruit rot

Lavie Bio's wheat field in the USA during harvest -

Sales initiated in 2022

Untreated control LAV3118 LAV312

Example of treatment against Botrytis Cinerea vs untreated control in vines

Lavie Bio Announces Commercial Launch of its First Microbiome-Based Product for Yield Improvement - Thrivus >

Thrivus "inoculant initially introduced for spring wheat in North Dakota, following positive four-year field trials

ICL and Lavie Bio Enter Strategic Collaboration to Develop Novel Bio-Stimulant Products

ICL to invest \$10 million in Lavie Bio

evogene

Powered by

Mission:

Design next-generation, effective and sustainable crop protection products by leveraging predictive biology & chemistry

Product Pipeline:

Herbicides

• Novel MoA (Mode-of-Action) selective/non-selective herbicides
• Relevant target crops including Cereals, Rice, Corn, Soybean, Cotton, Canola, Sugar Beet, Other TBD
• · Addressable market size expected by 2022*: \$34B

Insecticides

• · Novel SoA (Site-of-Action) resistance breaking
• · Addressable market size expected by 2022*: \$19B

Fungicides

• Novel MoA
• Relevant target crops including Cereals, Rice, Corn, Soybean, Cotton, Canola and Sugar Beet
• · Addressable market size expected by 2025*: \$24.5B

Expected main near-term value drivers:

2022

• · New MoA Herbicide identify collaboration partner, finalize business terms (term sheet)
• · New MoA Herbicide expand data package for APTH1, AgPlenus' leading new MoA protein for the development of novel herbicides

2023

• · New MoA Herbicide new collaboration agreement
• · New MoA Herbicide phase advancement in one of the ongoing collaborations
• · New MoA Fungicide program initial greenhouse readouts of designed compounds on target pest
• · Platform Tools POC recent AgTech raises focused on platform capabilities

*https://www.prnewswire.com/news-releases/global-3410-billion-herbicide-market-300458389.html; https://www.marketsandmarkets.com/Market-Reports/insecticide-market-142427569.html

evogene

Example Results:

New MoA Herbicide - APH1

Greenhouse testing of APH1 - modified tobacco plants with resistance trait vs unmodified control

evogene

AgPlenus Announces Reaching a 'Lead' Stage in its Novel Mode-of-Action Herbicide Program

This significant development milestone was achieved following positive results for product candidate APH1 in field tests with commercial level application rates on a broad panel of weeds

AgPlenus Announces Positive Results for a Herbicide Resistance Trait to its Leading Herbicide Product Candidate

Greenhouse proof-of-concept testing demonstrates resistance of modified model plants to AgPlenus' APH1 herbicide candidate

Powered by

Mission:

Commercialize effective, precise and stable medical cannabis products, based on decoding plant genetics, for optimized therapeutic effect and patient well-being

Product Pipeline:

MetaYield+ Products

High metabolite content & consumer traits

• · Stable enhancement of total plant compounds focused on THC, CBD and terpenes
• · Total cannabis market size expected by 2024 \$42.7B*

Precise+ Products

Therapeutic traits - focus on patients' well-being

• Stable enhancement of specific active compounds to address desired effects (e.g. pain management and reduced inflammation)
• · Total medical cannabis market size expected by 2024 \$25.6B*

Expected main near-term value drivers:

2022

• · MetaYield+ Commercial launch and sales of second generation products in Israel
• · Precise + Collect pre-clinical data to support commercial launch in 2023

2023

• · Commercial launch and initial sales of first product in Europe
• · Commercial launch of products addressing patients' well-being, such as reducing pain or inflammation

*Source: Arcview Market research/BDS Analytics 2020

evogene

Powered by

First Products:

The 'G-nnovation' series

G200 inflorescence

T20/C4 Indica

Top Reported Effects

• 1. Pain Relief
• 1. Relaxation
• 1. Improved quality sleep
• 1. Muscle Relaxation

G150 inflorescence

T20/C4 Sativa

Top Reported Effects

• 1. Pain Relief
• 1. Relaxation
• 1. Focus
• 1. Uplifting

evogene

Canonic Announces Full Commercial Launch of its First Medical Cannabis Products in Israel

Canonic moves ahead of schedule with the full commercial launch of its G-nnovation products, following positive feedback from patients during the company's pre-launch campaign

Canonic Announces Positive Results in Pre-Clinical Studies in its Precise Product Program for Medical Cannabis

The results support the successful identification of specific cannabis varieties with antiinflammatory and pain relief properties, for which Canonic recently filed a patent application

Canonic Announces Shipment of its Cannabis Varieties to Europe

Canonic is the first Israeli company shipping cannabis varieties from Israel to Europe, towards planned commercial launch in Europe in 2023

Main Subsidiaries: Industry Landscape

BIOMICA		lavie bio		agPlenus		(A) CANONIC
Microbiome Based Therapeutics		Ag-Biologicals		Ag-Chemicals		Medical Cannabis
Company	Market Cap/ Funds Raised	Company	Market Cap/ Funds Raised	Company	Market Cap/ Funds Raised	Company	Market Cap/ Funds Raised
UNEVELO	\$221m*	AGBIOME	Raised \$116m* (Sep 2021)	enko	Raised \$70m # (July 2022)	CRESCOLABS	\$1.1B*
FINCH >	\$124m*	. biotalys	€216m*	moa	Raised \$44m # (Jun 2022)	curaleaf	\$4.2B*
SERES	\$860m*	BIOCERES	\$860m*	Gerthbio	Raised \$55m* (Feb 2020)	IMCC	\$34m*
synlogic	\$77m*	PIVOT BIO	Raised \$430m \$2.0B # # rep. (July 2021)	115Metis	Raised \$10m* (Oct 2021)	S INTERCURE	\$221m*

* Public company - market cap as of September 12, 2022 (yahoo.finance.com). Bioceres subsidiaries not Marrone Bio Innovations.

Private company - amount raised in most recent financing round (crunchbase.com)

Private company - https://www.botes.com/steams-chilion-aluation-as-it-raiss-ihoping-130-million-is-relater-son-on-m-an-vinet-fedilizers-on-on-an-vinetsustainability/?sh=96ed3572273a

The table presents while thancing round for a selected unter of companis active in the same industries is our substitions is not a orgreses in is not a orgoneres in is not is only, There nay be signifiant offeen companis active in the eather on the table des not initiate potential vale for our substition which in the infraction presented in the table and nay offer signifiantly. Such difference naturity stage, volune of sales, f any product your naturity, technology, and finance position

evogene

Annex I - Financial Fundamentals

Computational systems biology Computational chemistry Bioinformatics Molecular biology Microbiology Genetics Biochemistry

Incl. chairperson
of the board

As of September 13, 2022

Summary

Revolutionizing life-science based product discovery & development, utilizing cutting edge computational biology technologies

Strong computational predictive biology (CPB) platform leveraging synergies between a deep understanding of biology, Big Data and AI

Business ecosystem for product development around tech engines MicroBoost AI, ChemPass AI & GeneRator AI

Computational Biology is an extremely attractive sector in its infancy with leading AI companies including Google newly involved

Dual based business model via subsidiaries or collaborations

Market-orientated subsidiaries generating value

• Biomica Human-microbiome based therapeutics
• Lavie Bio Ag-biologicals
• AgPlenus Ag-chemicals
• Canonic Medical cannabis

Significant catalysts to release value expected in the coming quatres

evogene

THANK YOU!

Annex I: Financial Fundamentals

evøgene

Key Financials: Balance Sheet

Key Points:

• · Consolidated cash position: ~\$35 million as of 30.06.2022, of which ~\$4 million is appropriated to Lavie Bio
• · In addition, Lavie Bio received \$10M in Q3 2022 from ICL
• · No bank debt
• · Full year net cash burn rate, excluding exchange rate impacts in 2022, is expected to be in the range of \$26-28 million (\$18-20 million excluding Lavie Bio)
• · Listed on TASE (2007) and NASDAQ (2016)

Thousands of US \$	30.06.2022	31.12.2021
Current Assets	37,705	56,890
Long-Term Assets	18,957	19,414
Total Assets	56,662	76,304
Current Liabilities	5,541	6,882
Long-Term Liabilities	5,724	6,002
Equity attributable to equity holders of the Company	36,949	53,653
Non-controlling interest	8,448	9,767
Total Liabilities & Shareholders Equity	56,662	76,304

evøgene